Bintrafusp alfa enhances the antitumor efficacy of anti-VEGF and VEGF receptor kinase inhibitors in preclinical solid tumor models.

被引：0
|
作者：
Yeung, Tsz-Lun [1 ]
Lazorchak, Adam [1 ]
Yu, Huakui [1 ]
Qi, Jin [1 ]
Qin, Guozhong [1 ]
Marelli, Bo [1 ]
Fu, Kai [1 ]
Lan, Yan [1 ]
机构：
[1] Serono Res & Dev Inst Inc, Billerica, MA USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
443
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Anti-VEGF Strategies - from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
    Korpanty, Grzegorz
    Smyth, Elizabeth
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (19) : 2680 - 2701
  • [22] The growth hormone receptor antagonist pegvisomant exhibits antitumor activity in multiple preclinical tumor models.
    Friend, K
    Flyvbjerg, A
    Bennett, W
    McCutcheon, I
    Anderson, MD
    CLINICAL CANCER RESEARCH, 2000, 6 : 4550S - 4550S
  • [23] EPI0030, a humanized anti-VEGF rabbit monoclonal antibody, exhibits potent activity in preclinical models
    Zhang, Yongke
    Ke, Yaohuang
    Lee, Pierre
    Yu, Qiu
    Zhu, Weimin
    Yu, Guo-Liang
    CANCER RESEARCH, 2009, 69
  • [24] BAY 87-2243, an inhibitor of HIF-1α activation and stabilization, showed promising anti-tumor efficacy either as monotherapy or in combination with anti-VEGF and chemotherapy agents in preclinical tumor models
    Berhoerster, Kerstin
    Ellinghaus, Peter
    Haerter, Michael
    Greschat, Susanne
    Wengner, Antje
    Scholz, Arne
    Haegebarth, Andrea
    Hess-Stumpp, Holger
    CANCER RESEARCH, 2011, 71
  • [25] Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs
    Hedlund, Eva-Maria Eleonora
    Yang, Xiaojuan
    Zhang, Yin
    Yang, Yunlong
    Shibuya, Masabumi
    Zhong, Weide
    Sun, Baocun
    Liu, Yizhi
    Hosaka, Kayoko
    Cao, Yihai
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (02) : 654 - 659
  • [26] Anti-tumor immunity and efficacy of combination treatment of M6223 and bintrafusp alfa versus the combination of M6223 and anti-PD-L1 in preclinical tumor models
    Xu, Chunxiao
    Yalavarthi, Sireesha
    Bourin, Clotilde
    Kelton, Christie
    Halle, Joern-Peter
    Moisan, Jacques
    CANCER RESEARCH, 2022, 82 (12)
  • [27] A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
    Brown, Jeffrey L.
    Cao, Z. Alexander
    Pinzon-Ortiz, Maria
    Kendrew, Jane
    Reimer, Corinne
    Wen, Shenghua
    Zhou, Joe Q.
    Tabrizi, Mohammad
    Emery, Steve
    McDermott, Brenda
    Pablo, Lourdes
    McCoon, Patricia
    Bedian, Vahe
    Blakey, David C.
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (01) : 145 - 156
  • [28] Collagen Signaling Enhances Tumor Progression after Anti-VEGF Therapy in a Murine Model of Pancreatic Ductal Adenocarcinoma
    Aguilera, Kristina Y.
    Rivera, Lee B.
    Hur, Hoon
    Carbon, Juliet G.
    Toombs, Jason E.
    Goldstein, Courtney D.
    Dellinger, Michael T.
    Castrillon, Diego H.
    Brekken, Rolf A.
    CANCER RESEARCH, 2014, 74 (04) : 1032 - 1044
  • [29] Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2024, 13 (03) : 227 - 234
  • [30] Efficacy of Anti-VEGF/VEGFR Agents on Animal Models of Endometriosis: A Systematic Review and Meta-Analysis
    Liu, Shuangge
    Xin, Xiaoyan
    Hua, Teng
    Shi, Rui
    Chi, Shuqi
    Jin, Zhishan
    Wang, Hongbo
    PLOS ONE, 2016, 11 (11):
12345